FORM PTO-1390 (Modified) U.S. DEP: STMENT OF COMMS (REV. 11-2000)

PATENT AND TRADEMARK OFFICE

TRASSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

Assignee: PHARMACIA ITALIA SPA of Milan, Italy

U.

KET NUMBER

17703 (PC27210A)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10/500606

INTERNATIONAL APPLICATION NO. **PCT/EP02/13092**

INTERNATIONAL FILING DATE

18 December 2002 (18.12.2002)

PRIORITY DATE CLAIMED

2 January 2002 (02.01.2002)

TITLE OF INVENTION

COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS

APPLICANT(S) FOR DO/EO/US

Maria Geroni, Camilla Fowst and Paolo Cozzi

	•	
Applicant herewith submits to the United States Designated/Ele	cted Office (DO/EO/US) the fo	llowing items and other information:

1.	×	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5) (6), (9) and (24) indicated below.					
4.	\boxtimes	The US has been elected by the expiration of 19 months from the priority date (Article 31).					
5.	X	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))					
		a. is attached hereto (required only if not communicated by the International Bureau).					
		b. 🛮 has been communicated by the International Bureau.					
		c. \square is not required, as the application was filed in the United States Receiving Office (RO/US).					
6. 🗆		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).					
		a. is attached hereto.					
		b. \square has been previously submitted under 35 U.S.C. 154(d)(4).					
7. 🛛 A		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))					
		a. are attached hereto (required only if not communicated by the International Bureau).					
		b. have been communicated by the International Bureau.					
		c. \square have not been made; however, the time limit for making such amendments has NOT expired.					
		d. 🛮 have not been made and will not be made.					
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).					
0.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).					
1.	\boxtimes	A copy of the International Preliminary Examination Report (PCT/IPEA/409).					
2.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).					
It	ems 1	3 to 20 below concern document(s) or information included:					
3.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
4.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
5.		A FIRST preliminary amendment.					
6.		A SECOND or SUBSEQUENT preliminary amendment.					
7.		A substitute specification.					
8.		A change of power of attorney and/or address letter.					
9.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.					
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).					
21.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					
22.	\boxtimes	Express Mail Label No. <u>EV213901318US</u>					
23.	\boxtimes	Other items or information:					
		Courtesy copy of International Application					

DT 2 Rec'd PCT/PTO 3 0 JUN 2004

0.5.74	1	0/500	606	PCT/EP02	2/1309	2		17703	3 (P	C27210A)
24.	The fol	lowing fees are subr	mitted:.					CALCULATIO	ONS	PTO USE ONLY
	BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :									
	Neither inter	mational preliminary search fee (37 CFR	y examination	fee (37 CFR 1.482) nor						
8	and Internat	ional Search Report	not prepared	by the EPO or JPO			\$1080.00			
⊠ i	Internationa	l preliminary examir	nation fee (37	CFR 1.482) not paid to ared by the EPO or JPO.			\$920.00			
	Internationa	l preliminary examir	nation fee (37	CFR 1.482) not paid to U(2)) paid to USPTO	JSPTO		\$770.00			
	Internationa	preliminary examin	nation fee (37	CFR 1.482) paid to USP T Article 33(1)-(4)	ТО		\$730.00			
	Internationa and all clain	I preliminary examir as satisfied provision	nation fee (37 ns of PCT Art	CFR 1.482) paid to USP icle 33(1)-(4)	TO		\$100.00		—	
		ENTER AP	PROPRI	ATE BASIC FEE	AMC	UI	NT =	\$920.0	00	
Surchar, months	ge of \$130.0 from the ear	00 for furnishing the liest claimed priorit	oath or decla y date (37 Cl		□ 20		⊠ 30	\$130.0)0	
CLA	IMS	NUMBER	FILED	NUMBER EXTRA			RATE			
Total cla	aims	27	- 20 =	7		х	\$18.00	\$126.0)0	
Indepen	dent claims	6	- 3=	3		х	\$86.00	\$258.0)0	
Multiple	e Dependent	Claims (check if a					_⊠	\$290.0	-	
		TC	TAL OF	ABOVE CALCU	LAT	[0]	<u>NS = </u>	\$1,724.0	201_	
□ Ap	plicant clair luced by 1/2	ns small entity statu	s. See 37 CFI	R 1.27. The fees indicated	above	are	_	\$0.0)0	
					SUBT	'O '	ΓAL =	\$1,724.0)0	
Processi months	ing fee of \$1 from the ear	30.00 for furnishing liest claimed priorit	g the English ty date (37 CI	translation later than FR 1.492 (f)).	□ 20		□ 30 +	\$0.0) 0	
				TOTAL NATIO	NAL	F	EE =	\$1,724.0	00	
Fee for accompa	recording th anied by an	e enclosed assignme appropriate cover sh	ent (37 CFR 1 neet (37 CFR	.21(h)). The assignment is 3.28, 3.31) (check if app	must be	 :).		\$0.0	00	
				TOTAL FEES EN			ED =	\$1,724.0	00	
						•		Amount to be: refunded	7	\$
								charged	\perp	\$
a.	X A cl	neck in the amount o	of \$1,72	4.00 to cover the abo	ve fees	is e	nclosed.			
b.	☐ Plea	se charge my Depos	it Account No	o in t	he amo	unt	of	to cove	er the	e above fees.
c.		Director is hereby a		charge any additional fees	which	may	be required	, or credit any over	rpayı	ment
						.:. £	am may ba	come nublic Cred	it ca	rd
a.	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: 1.137(a)	Where an) or (b)) mu	appropriate time li st be filed and grat	imit under 37 ated to restor	CFR 1.494 or 1.495 has te the application to pend	s not be	een i	met, a petiti	ion to revive (37 C	FR	
	, , , ,	ESPONDENCE TO				(Pet	15		_
Peter 1	I. Bernstein	, Esq.	· ·				GNATURE	71.		
Registration No. 43,497				31	UNATURE					
SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza				Peter I. Bernstein						
Garden City Plaza Garden City, New York 11530			NAME							
(516) 742-4343				43,497						
						RI	EGISTRATI	ON NUMBER		
						,In	ine 30, 200)4		
						_	ATE			
						ار.				

10/500606

CERTIFICATE OF I		MAIL" (37 CFR 1.10)12 Rec'd	PCT/Plocket No JUN 2004 17703 (PC27210A)
Serial No. Unassigned	Filing Date June 30, 2004	Examiner	Group Art Unit Unassigned
Invention: COMBINED DERIVATIV	THERAPY AGAINST TUMORS ES AND PROTEIN KINASE (SE	S COMPRISING SUBSTITUTED A CRINE/THREONINE KINASE) INH	CRYLOYL DISTAMYCIN IBITORS
I hereby certify that the New U.S. Application	e following correspondence: Under 35 USC 371		
	the United States Postal Servic	of correspondence) e "Express Mail Post Office to Add for Patents, P.O. Box 1450, Alexar	
	June 30, 2004 (Date)		
		Peter I. Bernstein (Typed or Printed Name of Person Mailing (Signature of Person Mailing Corre EV213901318US ("Express Mail" Mailing Label	g Correspondence) espondence)

Note: Each paper must have its own certificate of mailing.